Valuation
- Market cap
- 145,075,000
- Revenue TTM
- $0
- Net income TTM
- $-18,430,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 436,800
- Avg volume
- 818,034
- Day's range
- $1.10 – $1.20
- Shares out
- 127,259,000
- Stochastic %K
- 76%
- Beta
- 0.45
- Analysts
- Strong Sell
- Price target
- $8.00
Company profile
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system a...
Show more
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 44 20 7495 2379
- Website
- https://www.tizianalifesciences.com
- Address
- 14/15 Conduit Street, London, United Kingdom
Latest news
No headlines yet.
